FDA Approves Telix's Pixclara — First FET-PET Imaging Drug for Glioma
TLX sits 88% above its 52-week low of $6.28 on elevated volume (3.6× avg).
Summary
FDA approved Telix's Pixclara, the first FET-PET imaging drug for glioma, expanding its precision diagnostics franchise into brain cancer imaging.
Key Events · Product Development and Regulatory · TLX
-
FDA Approves Pixclara for Glioma Imaging
Pixclara (floretyrosine F 18) is the first FDA-approved FET-PET imaging drug for glioma, indicated for adults and pediatric patients 1 month and older.
-
Expands Commercial Diagnostics Portfolio
Pixclara becomes Telix's third FDA-approved product, joining Illuccix and Gozellix, and targets a U.S. market of approximately 24,000 new glioma cases per year.
-
Addresses Unmet Clinical Need
FET-PET imaging is recommended in international guidelines including NCCN, but no FDA-approved product was previously available in the U.S.
-
Phase 3 Expansion Study Underway
Pixclara (TLX101-Px) is also in a Phase 3 registrational study for potential indication expansion to brain metastases diagnosis.
Analysis · TLX · Life Sciences
The FDA has approved Pixclara, making it the first FET-PET imaging drug cleared for glioma. This milestone expands Telix's commercial diagnostics portfolio into brain cancer imaging, a market with roughly 24,000 new glioma cases diagnosed annually in the U.S. The approval addresses a significant unmet need and reinforces Telix's leadership in theranostics, adding a third FDA-approved product alongside Illuccix and Gozellix.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 37.4% of the 928 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.78%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TLX was trading at $11.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $6.28 to $12.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.